Watch and Learn

On demand educational videos

All of the GVF meeting videos are listed below. If you want to see only videos from one of the meetings, click the appropriate button below.

Nanja van Geel, MD, PhD walks you through the process of using the Vitiligo Extent Score (VES), VESplus, and Self Assessment Vitiligo Extent Score (SA-VES) to determine the VES score for a patient.

How to Use the VASI

Iltefat Hamzavi, MD walks you through the process of using the Vitiligo Area and Scoring Index (VASI) and the Vitiligo Area and Scoring Index for Face (F-VASI) to determine the VASI score for a patient.

Tasneem Mohammad, MD

Assessing the Reliability of Vitiligo Area Scoring Index with Digital Images of Vitiligo

Rania Mogawer, MBBch, MSc, MD

Comparative Analysis of vitiligo activity scores (VIDA versus VSAS) and extent scores (VES plus versus VASI)

Christian Russel Reyes, MS

An Analysis of Inter-Rater and Intra-Rater F-VASI Assessments in Adults with Active Non-Segmental Vitiligo

Marissa Ceresnie, DO

Measurement of Therapeutic Response Using the Vitiligo Area Scoring Index in People With Vitiligo: A Scoping Review

Gumma Sindhuri, MBBS

Colour conscious mind ( To investigate the impact of vitiligo on psychosocial and mental status of patients)

Nanja van Geel, MD, PhD

Invited Speaker: How to use the Vitiligo Extent Score (VES), VESplus and Self Assessment Vitiligo Extent Score (SA-VES)

John E. Harris, MD, PhD

Invited Speaker: Update on Vitiligo Pathogenesis

Vivek Natarajan, PhD

Exome-Sequencing of Vitiligo Lesions Indicate Lower Burden of Somatic Variations: Implications in Risk for Non-melanoma Skin Cancers

Meri Tulic, PhD, HDR

Impact of House Dust Mite in Vitiligo Skin: Environmental contribution to Increased Cutaneous Immunity and ‘Flying Melanocytes’

Archana Singh, PhD

Looking At The Brighter Side Of Vitiligo: Decoding Molecular Mechanisms behind Low Skin Cancer Incidence

Maha G. Tawfik, MSc

Immunohistochemical Tissue Expression of Mortalin in Vitiligo Patients

Joint Session

Vitiligo support group leaders share an update about vitiligo support groups around the globe.

Pearl Grimes, MD

Invited Speaker: The Changing Landscape of Childhood Vitiligo

Yasmin Tawfik, MD

The Efficacy of PRP in Management of Acral Vitiligo

Marwa Abdallah, MD

Efficacy and Safety of Diphenylcyclopropenone (DPCP) as a Depigmenting Therapy in Extensive Vitiligo- A Pilot Study

Thierry Passeron, MD, PhD

Invited Speaker: Optimizing Combination Therapies for the Best Results in Vitiligo

Meeting Wrap Up

Meeting Wrap up

Mauro Picardo, MD

Possible Source of the Intracellular Oxidative Stress in Vitiligo

Chau Yee Ng, MD, PhD

Elevated IFN-γ in Vitiligo Patient Skin Blisters: Potential Utility of Targeting IFN-γ for Therapy

Firdosh Shah, MSc

Compromised Melanocyte Survival Due to Decreased Suppression of CD4+ & CD8+ Resident Memory T Cells by Impaired TRM-Regulatory T Cells in Generalized Vitiligo

Shayna Aulakh, MBBS, MD

Differential Expression of Serum CXCL9 and CXCL10 in Vitiligo Patients and Their Correlation With Disease Severity and Stability

Hisham Hamdy, MBBS, MSc

Early Localized Vitiligo is not “EARLY”: A Tissue Resident Memory T Cell Study

Anuradha Bishnoi, MD

Assessing Expression of Immune Checkpoints Including Membrane-Bound and Soluble Programmed Death-1 Receptor and Ligands in Vitiligo and Correlating These With Serum Levels of Interleukin 2, 7, 15 and Vitiligo Disease Severity

Nader Ragab, MD

Oxidative Stress in Segmental Versus Non-Segmental Vitiligo

Rachel Carafello, MS

To What Extent Do Patient Demographics, Clinical Characteristics and Psychological Factors Explain Quality of Life in Vitiligo?

Laila Benzekri, MD

Predictive Factors of Thyroid Diseases in Vitiligo in Morocco

Hyun Jeong Ju, MD, PhD

New Classification and Treatment Outcome of Hand Vitiligo: A Cluster Analysis of 230 Patients

Rana Hilal, MD

Resident Memory T Cells in Non-segmental Vitiligo

Vinod Kumar, PhD

Role of CXCR3 and Its Primary Ligands in Segmental and Non-segmental Vitiligo Pathogenesis

Davinder Parsad, MD, FRCP​

Controversies & Challenges in the Pathophysiology of Vitiligo​ Interview and audience Q&A​

Samia Esmat, MD​

Targeting Innate & Adaptive Immunity as a Therapeutic Approach​ Interview and audience Q&A​

Yvon Gauthier, MD

Segmental Vitiligo Pattern and Cutaneous Arterial Vessel Mapping: An Anatomoclinical and Physiopathological Approach

Iltefat Hamzavi, MD ​

Outlining Vitiligo: Overview, Epidemiology & Burden of Disease​ Interview and audience Q&A​

Pfizer Satellite Meeting

Pfizer Satellite Meeting Vitiligo Talks: Understanding the Burden of Disease & Pathophysiology Panel discussion and audience Q&A​

Amit G. Pandya, MD

Invited Speaker: Update on Jak Inhibitors For Vitiligo

Abburi Ramaiah, PhD

Combinatorial Therapies With Basic Fibroblast Growth Factor Related Agonist Peptides to Treat Vitiligo

Thierry Passeron, MD, PhD

Effect of Ruxolitinib Cream on Achievement of VASI50 by Body Region: Week 52 Pooled Analysis of the TRuE-V Phase 3 Studies

Rania Mogawer, MBBch, MSc, MD

Effect of Narrow Band Ultraviolet B on the Tissue Level of Interleukin 15 and Interleukin 15 Receptor Alpha Subunit in Active Non Segmental Vitiligo Cases: An Interventional Cohort Study

Vidhya Narayan, MD

NB-UVB Phototherapy Response of Different Body Regions in Non-segmental Vitiligo

Marwa Abdallah, MD

Azathioprine Monotherapy vs Azathioprine-NB-UVB vs OMP-NB-UVB in Controlling Active Vitiligo, A Randomized, Controlled Study

Marissa Ceresnie, DO

Complimentary and Alternative Medicine Use in Vitiligo Patients

Samia Esmat, MD

Combination of Acitretin and Narrowband UV-B for the Treatment of Vitiligo: A New Treatment Modality With an Impact on Tissue E-cadherin Expression

Trilokraj Tejasvi, MD

Invited Speaker: Mimickers of Vitiligo

Marwa Abdullah, MD

Invited Speaker: Updates on Surgical Management of Vitiligo

Somesh Gupta, MD

Comparison of Laboratory Indicators and Clinical Efficacy of Non-cultured Epidermal Cell Suspension and Hair Follicle Cell Suspension in Surgical Management of Stable Vitiligo: A Randomized Trial

Nikhil Mehta, MD

Long-Term Outcomes and Patient Satisfaction With Vitiligo Surgeries

Hasan El-Fakahany, MD

Use of Micro Short Pulse Erbium Yag Laser for Management of Vitiligo and Leukotrekia

Jung Min Bae, MD, PhD

Motorized 0.5/0.8-Mm Micropunch Grafting to Treat Refractory Vitiligo: A Retrospective Study of 1,066 Cases

Noufal Raboobee, MD

Combination of Needling and 308 Excimer Light for Treatment of Vitiligo

Rania Mogawer, MBBch, MSc, MD

Value of Adding Platelet Rich Plasma (PRP) To Non-cultured Epidermal Cell Suspension (NCES) In Surgical Treatment of Stable Resistant Vitiligo: A Self-Controlled Randomized Double-Blinded Study

Drs. Ezzedine and Mysrore

Update on the Global Vitiligo Atlas

Manju Daroach, MD

An Overview of Pathomechanism of Vitiligo

Binod Khaitan, MD

Autoimmunity and Vitiligo

Sanjay Dubey, MD

Recent Advances in Phototherapy of Vitiligo

Sendhil M Kumaran, MD

Immunosuppressive Therapy in Vitiligo : An Update

Mahesh Kumar Verma, MD

Small Molecule AB1001 as a Topical Non-steroidal Therapeutic Approach for Vitiligo

Deepti Ghia, MD

Case-Based Approach for Difficult-To-Treat Vitiligo

Ramaiah Abburi, MD

Topical Decapeptide in Vitiligo

Imran Majid, MD

Targeted Phototherapy in Vitiligo

Madhulika Mhatre, MD

Controversies and Current Recommendations for Stability of Vitiligo

Dilip Kachhawa, MD

Perilesional Skin as a Donor in Vitiligo Patches by Jodhpur Technique

Sahil Mrigpuri, MD

Preparation of NCECS in Stromal Vascular Fraction

Munish Paul, MD

Depigmentation in Vitiligo: Combination Approach With Lasers and Medications

Muhammed Razmi, MD

Can a Long-Term Favorable Micro Environment Yield Repigmentation in Acral Vitiligo?

Iltefat Hamzavi, MD

The Intersection of Society, Science and Therapeutics: How We All Built Our Vitiligo Community

Kanika Sahini, MD

Camouflage in Vitiligo

Panel Discussion

Panel Discussion - Vitiligo: How close are we to a cure?

Panel Discussion

Panel: Cracking Your Hardest Cases Using Systemic Treatments and Case Studies to Improve Your Vitiligo Treatment Skills

David Rosmarin, MD

Invited Speaker: Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo: 24-Week Results From 2 Randomized, Double-Blind Phase 3 Studies

Prashant Giri, MSc

Altered Calcium-NFAT Signaling Pathway May Be Responsible for Decreased Suppressive Capacity of Tregs in Generalized Vitiligo Patients

Janice Nathalie, MD

/
Health-Related Quality of Life in Pediatric Patients With Vitiligo

Thierry Passeron, MD, PhD Oral Abstract

Increased Cutaneous Activation of Innate Immunity and Pro-apoptotic CXCR3B in Patients With Segmental Vitiligo

Davinder Parsad, MD

Invited Speaker: Stabilizing Treatment Options in Vitiligo

Andrew Thompson, DClinPsy

/
The Association Between Mental Health Conditions and Vitiligo: A Population-Based Cohort Study in the UK

Nanis Ragab, MD

Early Localized Vitiligo, a Medical Emergency: Long Term Follow up Study

Jessica Shiu, MD, PhD

Multimodal Analyses of Stable Vitiligo Skin Identify Tissue Interactions That Control Disease Persistence

Poster Session Q&A #3

Laila Benzekri, MD Avina Jain, MBBS, MD Reenu T. George, MD Prakhar Srivastava, MBBS, MD

Samia Esmat, MD

Vitiligo Treatment: Patient’s or Doctor's Decision ?!!

Rania Mogawer, MD

Efficacy of Narrow Band UVB With or Without Oral Mini-Pulse Steroids in Stabilization of Vitiligo Activity in Skin Phototypes (III -V): A Double Blind Randomized Placebo Controlled Prospective Multi-Center Study

Marissa Ceresnie, DO

Investigating Disparities in Recording Race and Ethnicity in Vitiligo Clinical Trial Screening Assessments

Monica Ottaviani, PhD

Vitiligo: The Skin Barrier Point of View

Jayvadan Vaishnav, MSc

Involvement of VTCN1 and Its Cleaving Enzyme NRD1 in Vitiligo Pathogenesis

Ahmed Mourad, MBBS, MS

Assessment of Tissue PD-1 and PD-l1 Levels in Vitiligo Patients (Case Control Study)

Poster Session Q&A #4

Sanjay Kumar Kanodia, MD Paras Choudhary, MD Nicoline Post, MD Alexandria Brown, BSA

Thierry Passeron, MD, PhD

Invited Speaker: Oral Gliadin-Protected Superoxide Dismutase in Addition to Phototherapy for Treating Non-segmental Vitiligo: A 24-Week Prospective Randomized Placebo-Controlled Study

Hyun Jeong Ju, MD

Progressive and Extensive Hypomelanosis of Childhood: A Novel Disease Entity Distinguished from Other Hypomelanotic Disorders

Marcella Willemsen, MSc

Immunophenotypic Analysis Reveals Differences in Circulating Immune Cells in Peripheral Blood of Segmental and Non-segmental Vitiligo Patients

Nanja van Geel, MD, PhD and Jolien Duponselle, MD

Image Analyses Systems to Calculate the Surface Area of Vitiligo Lesions: A Systematic Review of Measurement Properties

Caroline Le Poole, PhD

Invited Speaker: Modeling Microbial Impact on Autoimmune Depigmentation in Mice

Saurabh Bhatia, MD

Efficacy of NB-UVB in Progressive Versus Non-progressive Non-segmental Vitiligo: A Prospective Comparative Study

2021 VIS Khaled Ezzedine, MD, PhD

Efficacy and Safety of the Oral Janus Kinase 3/Tec Inhibitor Ritlecitinib (PF-06651600) In Adults With Active Non-segmental Vitiligo: Results From a Phase 2b, Randomized, Dose-Ranging Study With an Extension Period

Beth Schneider, PhD

Research - MyVitiligoTeam (Social Network)

Poster Q&A Session #1

Shiwangi Rana, MD; Alpana Mohta, MD; Ju Hee Han, MD; Fabiana Castro Porto Silva Lopes, MD;

Mauro Picardo, MD

/
Invited Speaker - Vitiligo: A Diverse Perspective

Nicoline Post, MD

Meek Micrografting: A Novel Surgical Technique for the Treatment of Depigmentation

Helen Kitchen, MSc

A Qualitative Study to Explore the Content Validity of the Vitiligo Patient Priority Outcome (ViPPO) Measures

Camille Robinson, BS

Assessment of Vitiligo Patients’ Perceptions and Opinions About Their Dermatologists When They Were First Diagnosed

Marcella Willemsen, MSc Invited Speaker

Vitiligo Up-and-Coming Invited Speaker: Impaired Ifn-γ-Induced PD-L1 Expression on Human Vitiligo Melanocytes

Poster Session Q&A #2

Lamia Elgarhy, MD; Yvon Gauthier, MD; Jalal Maghfour, MD; Nicole Syder, BA

Q&A Session #4

Iltefat H. Hamzavi, MD, FAAD – Invited Speaker

Phototherapy for Vitiligo: How to Optimize and What the Future Holds

Simone Nichole Boeckmann Montgomery, BA

Vitiligo and Psychological Comorbidities: A Retrospective Analysis in an Urban Population

Youwen Zhou, MD, PhD

Therapeutic Response Biomarkers for Vitiligo Patients on Narrow Band UVB and Topical Tacrolimus Combination Therapy

Haitham M. Saleh, Msc

A Comparative Pilot Study of Dipstick versus Open-Spray Cryotherapy Techniques as Depigmentation Treatments for Vitiligo

Davinder Parsad, MD

Recent Advances in the Surgical Management of Vitiligo

Q&A Session #3

Jung Min Bae, MD, PhD Oral Abstract

An Identification of Potential Therapeutics for Vitiligo by Mass Screening for 1,732 Medicines in Korean National Health Insurance Database

John E. Harris, MD, PhD – Oral Abstract

Survey Investigating the Prevalence of Vitiligo and Vitiligo Signs among Adults in Europe, Japan, and the United States

Saad Altalhab, MBBS

Risk Factors of Infection Post Non-cultured Melanocyte Keratinocyte Transplantation for Vitiligo

AMIT G. PANDYA, MD

Advances in Treatment of Vitiligo With JAK Inhibitors

Meri K. Tulic, PhD

Analysis of Matched Skin and Gut Microbiome of Vitiligo Patients Reveals Dysbiosis in Lesional Skin: Association with Mitochondrial Damage and Changes in Immune Function

Victor Huang, MD

An Open-Label Pilot Study of Abatacept (CTLA4-Ig) for the Treatment of Nonsegmental Vitiligo

Iltefat H. Hamzavi, MD, FAAD Oral Abstract

Analysis of 24-Week Response to Ruxolitinib Cream for the Treatment of Vitiligo Based on Patient Demographics and Clinical Characteristics

Nanja van Geel, MD, PhD

International Collaborative Project to Standardize the Assessment and Monitoring of Vitiligo in Clinical Trials, Registries and Clinical Practice

Q&A Session #2

Julien Seneschal, MD, PHD

Vitiligo: Looking at the Memory T Cell Response

Jesslyn Alyce Magee, MS

Pilot Network Model for Automated Vitiligo Lesion Segmentation: Promise and Challenges

Nanja van Geel, MD, PhD – Oral Abstract

Influencing Factors on the Patient Global Assessment Score for Vitiligo Severity

Pearl Grimes, MD

Effects of Ruxolitinib Cream on Affected Body Areas in Patients with Vitiligo: Subgroup Analysis from a 52-Week, Randomized, Double-Blind Trial

John E. Harris, MD, PhD

Advances In Immune Mechanisms Of Vitiligo

Q&A Session #1

Chris O’Brien

Patient Stories, Data and Demo – MyVitiligoTeam (Patient Social Network)

Vidhya Shankar Narayan, MD

Donor to Recipient Ratios in the Surgical Treatment of Vitiligo and Piebaldism: A Systematic Review

Jung Min Bae, MD, PhD

Vitiligo and Comorbidity: A Comprehensive Review

Pankhuri Dudani, MBBS

Effects of Adding PRP to Microneedling Plus 5-Fluorouracil Therapy in Acral Vitiligo: A Split-Body Randomized Trial

Mahajabeen Saheb Patel Madarkar, MD

Comparative Study of Safety and Efficacy of Oral Betamethasone Pulse Therapy and Azathioprine in Vitiligo

Khaled Ezzedine, MD, PhD

Prevalence of Psychosocial Comorbidities in Vitiligo: A Systematic Literature Review

Richard A. Spritz, MD

Genetic And Environmental Correlates Of Vitiligo